Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

Rhea-AI Summary

Harrow (Nasdaq: HROW) announced three scientific abstracts accepted for presentation at the ASCRS 2026 Annual Meeting, April 10–13 in Washington, D.C. The studies feature Harrow commercial products VEVYE 0.1% and ILEVRO 0.3% covering dry eye disease and post-cataract surgery outcomes.

Presentations occur April 11–12 and will release detailed data at session times listed by the company.

News Market Reaction – HROW

-2.13%

1 alert

-2.13% News Effect

On the day this news was published, HROW declined 2.13%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Number of abstracts: 3 abstracts VEVYE concentration: 0.1% ILEVRO concentration: 0.3% +3 more

6 metrics

Number of abstracts 3 abstracts Accepted for ASCRS 2026 Annual Meeting

VEVYE concentration 0.1% Cyclosporine ophthalmic solution for dry eye disease

ILEVRO concentration 0.3% Nepafenac ophthalmic suspension for cataract surgery patients

ASCRS 2026 dates April 10–13, 2026 Annual Meeting in Washington, D.C.

Ocular Surface session 8:00–9:30 AM Session on April 11, 2026

Medications session 8:00–9:30 AM Session on April 12, 2026

Market Reality Check

Price: $34.41 Vol: Volume 596,518 is at 0.55...

low vol

$34.41 Last Close

Volume Volume 596,518 is at 0.55x the 20-day average, indicating muted trading interest ahead of the meeting. low

Technical Shares at $35.23 are trading below the 200-day MA of $40.37, reflecting a weaker intermediate-term trend despite this positive visibility update.

Peers on Argus

Sector peers show mixed, mostly modest moves (e.g., PAHC up 2.38%, BGM down 5.21...

1 Up

Sector peers show mixed, mostly modest moves (e.g., PAHC up 2.38%, BGM down 5.21%), and only one momentum peer (PCRX up 2.96%) appears. With limited, non-uniform peer strength, this looks more company-specific than a sector-wide move.

Historical Context

5 past events · Latest: 2026-03-04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-03-04	Conference presentation	Neutral	+1.6%	Announcement of participation in Leerink Partners’ 2026 Global Healthcare Conference.
2026-03-03	Phase 3 trial plan	Positive	-28.0%	FDA-cleared IND to initiate Phase 3 trial expanding TRIESENCE label post-cataract surgery.
2026-03-02	Earnings and guidance	Positive	-28.0%	Record Q4 and 2025 revenue with positive Adjusted EBITDA and strong 2026 guidance.
2026-02-18	Earnings date notice	Neutral	-1.3%	Scheduling announcement for Q4 and full-year 2025 results and related webcast.
2026-02-17	Product program launch	Positive	+6.0%	Launch of PharmaPack cash-pay kits as alternatives to compounded ophthalmic products.

Pattern Detected

Recent history shows several sharp negative reactions to otherwise constructive clinical and earnings updates, indicating a pattern of downside divergence on ostensibly positive news.

Recent Company History

Over the last month, Harrow has reported multiple milestones. On Feb 17, it launched the PharmaPack cash-pay program, coinciding with a 5.98% gain. However, record Q4 and 2025 results with strong $272.3M revenue and bullish 2026 guidance on Mar 2 were followed by a -27.96% move, mirrored the next day after a Phase 3 TRIESENCE® trial announcement. Today’s ASCRS abstract acceptances add scientific visibility, fitting into a stream of ongoing commercial, clinical, and investor-relations activity.

Market Pulse Summary

This announcement highlights growing clinical evidence around Harrow’s commercial assets, with three...

Analysis

This announcement highlights growing clinical evidence around Harrow’s commercial assets, with three abstracts on VEVYE and ILEVRO accepted for ASCRS 2026. It follows recent milestones in earnings, guidance, and late-stage clinical planning. Investors may watch for the quality of real-world and post-hoc data, how these findings support differentiation versus alternatives, and whether future updates more clearly connect scientific visibility to revenue and label-expansion opportunities.

Key Terms

ophthalmic, cyclosporine ophthalmic solution, nepafenac ophthalmic suspension, ocular surface disease, +4 more

8 terms

ophthalmic medical

"a leading provider of ophthalmic disease management solutions in North America"

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

cyclosporine ophthalmic solution medical

"VEVYE® (cyclosporine ophthalmic solution) 0.1% and ILEVRO®"

A cyclosporine ophthalmic solution is a prescription eye drop that contains the drug cyclosporine to calm immune-driven inflammation on the surface of the eye and help restore natural tear production. Think of it like a targeted tune-up for a dry, irritated eye: it addresses underlying inflammation rather than just masking symptoms. Investors watch it because approval status, patent protection, manufacturing scale, and safety data directly affect a drug’s sales potential and a company’s valuation.

nepafenac ophthalmic suspension medical

"ILEVRO® (nepafenac ophthalmic suspension) 0.3% have been accepted"

Nepafenac ophthalmic suspension is a prescription anti-inflammatory eye drop used to prevent or reduce pain and swelling in the front of the eye, often after cataract surgery or for certain inflammatory eye conditions. It matters to investors because its sales, regulatory approvals, patent protection and competition determine revenue potential and risk for companies that make or sell it — like a single, in-demand component whose market exclusivity and price affect a manufacturer's earnings.

ocular surface disease medical

"The abstracts will be presented in the following scientific sessions: Ocular Surface Disease"

A group of conditions that damage the eye’s outermost layers — the tear film, cornea and conjunctiva — causing symptoms like dryness, redness, pain and blurred vision. Think of it as skin problems for the eye or a scratched windshield that scatters light; it matters to investors because it drives demand for prescription drugs, medical devices and ongoing care, creating recurring revenue streams and regulatory milestones that can affect company value.

keratoplasty medical

"as an Alternative to Corticosteroids in Post-Fungal Keratoplasty Presenter"

Keratoplasty is a surgical procedure that repairs or replaces the cornea, the clear front window of the eye, to restore vision or treat damage. Think of it like replacing or patching a cracked windshield so light can pass through clearly; the outcome affects patient demand for related devices, drugs and services and can influence regulatory approvals, reimbursement and revenue prospects for healthcare and medical-technology companies.

macular edema medical

"visual acuity loss associated with cataract surgery in subjects with Macular Edema"

Macular edema is a buildup of fluid in the macula, the small central part of the eye responsible for sharp, straight-ahead vision, which causes blurred or distorted sight as if looking through a smudged camera lens. For investors it matters because the condition drives demand for treatments, influences clinical trial results and regulatory approvals, and can change a company’s sales and valuation when new drugs or devices prove effective or fail.

post-hoc analysis medical

"ILEVRO: Post-Hoc Analysis of the Effect of Nepafenac 0.3%"

Post-hoc analysis is an examination of data carried out after an experiment, trial, or reporting period to look for patterns or explanations that were not specified beforehand. It matters to investors because such findings can suggest new opportunities or risks but are more likely to be chance results than preplanned conclusions, so they require independent confirmation before being treated as reliable — like noticing a pattern on a map after a trip and then testing it on the next journey.

cataract surgery medical

"visual acuity loss associated with Cataract Surgery in subjects with Macular Edema"

A surgical procedure that removes a cloudy natural lens in the eye and usually replaces it with a clear artificial lens, restoring vision much like cleaning or replacing a fogged camera lens to get a sharp picture again. It matters to investors because the procedure drives demand for medical devices, implants, surgical equipment and related services, so changes in procedure volume, technology, pricing or reimbursement can directly affect revenue and growth prospects for healthcare companies.

AI-generated analysis. Not financial advice.

NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products VEVYE^® (cyclosporine ophthalmic solution) 0.1% and ILEVRO^® (nepafenac ophthalmic suspension) 0.3% have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting, taking place April 10–13 at the Walter E. Washington Convention Center in Washington, D.C.

The accepted research underscores Harrow’s continued commitment to advancing evidence-based treatment options for ophthalmic diseases, including dry eye disease and post-cataract surgery complications.

The abstracts will be presented in the following scientific sessions:

Ocular Surface Disease
Date: Saturday¸ April 11, 2026
Time: 8:00 AM – 9:30 AM

• VEVYE: Real-World Treatment Patterns and Clinical Outcomes with Cyclosporine 0.1% in Semifluorinated Alkane for Dry Eye Disease
  • Presenter: A. Epitropoulos, MD

• VEVYE: Dual-Function Cyclosporine 0.1% in Perfluorobutylpentane as an Alternative to Corticosteroids in Post-Fungal Keratoplasty
  • Presenter: T. Shoshany, MD

Medications (Preoperative, Postoperative, Intraoperative)
Date: Sunday, April 12, 2026
Time: 8:00 AM – 9:30 AM

• ILEVRO: Post-Hoc Analysis of the Effect of Nepafenac 0.3% on Reducing Clinically Significant Visual Acuity Loss Associated with Cataract Surgery in subjects with Macular Edema
  • Presenter: I. Mac, MD

The ASCRS Annual Meeting is one of the world’s premier gatherings for ophthalmic surgeons and ophthalmic professionals, showcasing the latest clinical research, surgical techniques, and therapeutic innovations in ophthalmology.

Additional details regarding the abstracts and supporting data will be available at the time of presentation.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contacts:
Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890

FAQ

What will Harrow (HROW) present at ASCRS 2026 and when are the sessions?

Harrow will present three abstracts on April 11–12, 2026 at ASCRS 2026 in Washington, D.C. According to the company, two VEVYE abstracts appear in Ocular Surface Disease on April 11 (8:00–9:30 AM) and one ILEVRO abstract appears April 12 (8:00–9:30 AM).

Which Harrow products (HROW) are featured in the ASCRS 2026 abstracts?

The abstracts highlight Harrow's VEVYE 0.1% and ILEVRO 0.3% ophthalmic therapies. According to the company, VEVYE focuses on dry eye and post-fungal keratoplasty topics while ILEVRO covers effects on visual acuity related to cataract surgery with macular edema.

How can investors view the Harrow (HROW) ASCRS 2026 presentation details?

Investors can view session schedules at the ASCRS meeting and seek company materials at presentation times. According to the company, additional abstract details and supporting data will be released at the time of each presentation during the April 11–12 sessions.

Does Harrow (HROW) claim clinical outcomes for VEVYE 0.1% in the ASCRS abstracts?

The company reports abstracts examining real-world treatment patterns and outcomes for VEVYE 0.1%. According to the company, one abstract reports real-world use and outcomes while another evaluates dual-function cyclosporine as an alternative in post-fungal keratoplasty.

What is the focus of the ILEVRO 0.3% abstract Harrow (HROW) will present?

The ILEVRO abstract presents a post-hoc analysis on reducing clinically significant visual acuity loss after cataract surgery in patients with macular edema. According to the company, the analysis examines nepafenac 0.3% effects on visual acuity in that surgical subgroup.